TRPA1 Inhibition Effects by 3-Phenylcoumarin Derivatives
Sallomy, Carita; Awolade, Paul; Rahnasto-Rilla, Minna; Hämäläinen, Mari; Nousiainen, Liisa P.; Johansson, Niklas G.; Hiltunen, Sanna; Turhanen, Petri; Moilanen, Eeva; Lahtela-Kakkonen, Maija; Timonen, Juri M. (2024)
Sallomy, Carita
Awolade, Paul
Rahnasto-Rilla, Minna
Hämäläinen, Mari
Nousiainen, Liisa P.
Johansson, Niklas G.
Hiltunen, Sanna
Turhanen, Petri
Moilanen, Eeva
Lahtela-Kakkonen, Maija
Timonen, Juri M.
2024
ACS MEDICINAL CHEMISTRY LETTERS
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-2024121211062
https://urn.fi/URN:NBN:fi:tuni-2024121211062
Kuvaus
Peer reviewed
Tiivistelmä
Transient receptor potential ankyrin 1 (TRPA1) protein plays an important role in the inflammatory response, and it has been associated with different pain conditions and pain-related diseases, making TRPA1 a valid target for painkillers. In this study, we identified potential TRPA1 inhibitors and located their binding sites utilizing computer-aided drug design (CADD) techniques. The designed 3-phenylcoumarin-based TRPA1 inhibitors were successfully synthesized using a microwave assisted synthetic strategy. 3-(3-Bromophenyl)-7-acetoxycoumarin (5), 7-hydroxy-3-(3-hydroxyphenyl)coumarin (12) and 3-(3-hydroxyphenyl)coumarin (23) all showed inhibitory activity toward TRPA1 in vitro. Compound 5 also decreased the size and formation of breast cancer cells. Hence, targeting TRPA1 may represent a promising alternative for the treatment of pain and inflammation.
Kokoelmat
- TUNICRIS-julkaisut [24210]